Clinical Trial Update: Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a genetic profile–guided treatment strategy for ovarian cancer patients who previously received a PARP inhibitor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Endometrioid Cancer
• High-grade Serous Cancer
• Ovarian Cancer
• Peritoneal Cancer

Snippet

Sponsor: University Health Network, Toronto | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: UNKNOWN